IVRCC IVR, IWR solutions for Oncology Clinical Trials and Studies

Our team is experienced in providing ePRO, randomization and CTM services for Oncology registries and Phase I-IV Clinical Trials. IVR Clinical Concepts provides Oncology clinical trial services including ePRO and IVR/IWR and Clinical Trial Material Management (CTM).

Client Indication Phase Description Countries Sites Subjects
Biopharma Ovarian Cancer

II

Site users use administrative account reviewed application to self-register to phase II study. Sites register/randomize subjects and generate User ID and initial Pass-code to provide to subjects to self-register to diary. Sites and subjects received email notifications when registered. Site Trial Supply Management included receipt of CTM, dispensation notifying pharmacist of treatment group in real-time. System provided virtually instant email notification confirmations and appropriate blinded or unblinded reporting to Site users and Pharmacists.

USA/EU

25

80

Top 10 Pharma Chronic Myelogenous Leukemia (CML)

Registry

IWR/IMR ePRO, validated FACT instruments, subjects self-register, alert text/email to subjects when diary window was OPEN and warning text/email as diary neared its CLOSE.

USA

30

170

Top 10 Pharma Metastatic Renal Cell Carcinoma (MRCC)

Registry

IWR/IMR ePRO, validated FACT instruments, subjects self-register, notification to subjects when diary available.

USA

60

500

Top 10 Pharma Breast Cancer

Registry

Off-site subject self registration to 5 year study, with reminder notifications at predetermined 1 month, 3 month, 6 month and annual intervals.

Italy, Germany

50-80

500

Top 10 Pharma Breast Cancer

Registry

Sites registered subjects to IWR/IMR subject scheduled validated questionnaires using IWRS. Subjects self-registered voluntarily to diary in real-time at first visit. iOS devices provisioned for study use as needed. 100 sites, 1500 subjects over a total of 5 years.

USA

100

1500

Large Biopharma Breast Cancer

IIb

IVRS registration and ePRO to record the time of patient’s self injection of GMCSF to prevent reduction in white blood cell count; record body temperature at least 4 hours after each as a measure of infection

USA

8 48
Mid-size BioPharma Research GI Cancer/Thrombosis

IV

Site users randomized subjects using centralized web-based application, 62 sites, 740 subjects.

India

62

740

 
 

 

 

Schedule a Demonstration

 

Contact us to arrange a complete online demonstration of our Interactive Voice and Web Response solutions.

Our team is ready to demonstrate key features, answer your questions, and explore how we help can make your next project a success.

 

Schedule a Demo

IVRCC ePRO solutions for Clinical Trials